Performance Summary - China Railway Construction (01186.HK) reported a revenue of 489.2 billion yuan, a decrease of 5.2% year-on-year, with a net profit of approximately 10.7 billion yuan, down 10.1% [2] - Industrial and Commercial Bank of China (01398.HK) achieved a revenue of 409.1 billion yuan, an increase of 1.8% year-on-year, while net profit fell by 1.4% to 168.1 billion yuan [2] - Agricultural Bank of China (01288.HK) recorded a revenue of 369.79 billion yuan, up 0.7% year-on-year, and a net profit of 139.51 billion yuan, an increase of 2.66% [2] - China Construction Bank (00939.HK) reported a revenue of 385.91 billion yuan, a 3% increase year-on-year, with net profit around 162.08 billion yuan, down 1.4% [2] - Bank of China (03988.HK) had a revenue of 329.42 billion yuan, up 3.61% year-on-year, while net profit decreased by 0.85% to 117.59 billion yuan [2] - Postal Savings Bank of China (01658.HK) reported a revenue of 179.53 billion yuan, a 1.5% increase year-on-year, with net profit of 49.23 billion yuan, up 0.85% [2] - China Merchants Bank (03968.HK) achieved a revenue of 169.92 billion yuan, down 1.7% year-on-year, while net profit increased by 0.3% to 74.93 billion yuan [2] - Bank of Communications (03328.HK) reported a revenue of 133.50 billion yuan, up 0.7% year-on-year, with net profit of 46.02 billion yuan, an increase of 1.6% [2] - Minsheng Bank (01988.HK) had a revenue of 70.70 billion yuan, up 7.8% year-on-year, while net profit decreased by 4.9% to 21.38 billion yuan [2] - China Everbright Bank (06818.HK) reported a revenue of 65.95 billion yuan, down 5.6% year-on-year, with net profit of 24.62 billion yuan, an increase of 0.55% [2] - BYD Company (01211.HK) achieved a revenue of 371.28 billion yuan, up 23.3% year-on-year, with net profit of 15.51 billion yuan, an increase of 13.8% [2] - China Communications Construction Company (01800.HK) reported a revenue of 335.45 billion yuan, down 5.8% year-on-year, with net profit of 9.99 billion yuan, down 16.9% [2] - Lenovo Holdings (03396.HK) achieved a revenue of 281.59 billion yuan, up 21% year-on-year, with net profit of 699 million yuan, an increase of 144% [2] - Great Wall Motors (02333.HK) reported a revenue of 92.34 billion yuan, up 1% year-on-year, with net profit of 6.34 billion yuan, down 10.2% [2] - BYD Electronics (00285.HK) achieved a revenue of 80.61 billion yuan, up 2.6% year-on-year, with net profit of 1.73 billion yuan, an increase of 14% [2] - Country Garden (02007.HK) reported a revenue of 72.57 billion yuan, with a net loss of 19.078 billion yuan [2] - China Reinsurance (01508.HK) achieved a revenue of 61.03 billion yuan, up 0.6% year-on-year, with net profit of 6.244 billion yuan, an increase of 9.03% [2] - Yanzhou Coal Mining Company (01171.HK) reported a revenue of 53.966 billion yuan, down 13.17% year-on-year, with net profit of 4.731 billion yuan, down 38.7% [2] - Jitu Express (01519.HK) achieved a revenue of 5.499 billion USD, up 13.1% year-on-year, with net profit of 156 million USD, an increase of 147.1% [2] - AVIC Industry (02357.HK) reported a revenue of 37.465 billion yuan, up 11.43% year-on-year, with net profit of 1.03 billion yuan, down 17.67% [2] - CITIC Financial Assets (02799.HK) achieved a revenue of 31.136 billion yuan, up 2.9% year-on-year, with net profit of 6.168 billion yuan, an increase of 15.7% [2] - Bank of China Hong Kong (02388.HK) reported a net interest income of 25.06 billion HKD, down 3.5% year-on-year, with net profit of 22.12 billion HKD, an increase of 10.54% [2] - Zoomlion Heavy Industry (01157.HK) achieved a revenue of 24.855 billion yuan, up 1.3% year-on-year, with net profit of 2.765 billion yuan, an increase of 20.84% [2] - New Town Development (01030.HK) reported a revenue of 22.1 billion yuan, down 34.82% year-on-year, with net profit of 895 million yuan, down 32.11% [2] - Huatai Securities (06886.HK) achieved a revenue of approximately 20.98 billion yuan, up 5.86% year-on-year, with net profit of 7.549 billion yuan, an increase of 42.16% [2] - China Sanjiang Chemical (02198.HK) reported a revenue of 9.106 billion yuan, down 1.5% year-on-year, with net profit of 301 million yuan, an increase of 95.5% [2] - Tianjin Bank (01578.HK) achieved a revenue of 8.828 billion yuan, up 0.8% year-on-year, with net profit of 1.988 billion yuan, an increase of 1.1% [2] - Harbin Bank (06138.HK) reported a revenue of 7.386 billion yuan, up 2.6% year-on-year, with net profit of 915 million yuan, an increase of 20% [2] - Qingjian International (01240.HK) achieved a revenue of approximately 4.404 billion HKD, down 9.8% year-on-year, with net profit of 2.992 million HKD, an increase of 25.6% [2] - Xingye Alloy (00505.HK) reported a revenue of 4.389 billion yuan, up 22.1% year-on-year, with net profit of 106 million yuan, down 24.7% [2] - 3SBio (01530.HK) achieved a revenue of 4.355 billion yuan, down 0.8% year-on-year, with net profit of 1.358 billion yuan, an increase of 24.6% [2] - Huya Technology (01860.HK) reported a revenue of 938 million USD, up 47% year-on-year, with adjusted EBITDA of 88.681 million USD, an increase of 41% [2] - Haitong Securities (01905.HK) achieved a revenue of 3.521 billion yuan, down 12.6% year-on-year, with net profit of 785 million yuan, down 3.4% [2] - Dazhong Public Utilities (01635.HK) reported a revenue of approximately 3.449 billion yuan, down 5.8% year-on-year, with net profit of approximately 333 million yuan, an increase of 172.6% [2] Company News - China Biologic Products (01177.HK) received approval for the launch of Zongaitini tablets for the treatment of HER2-mutant non-small cell lung cancer [3] - Shandong High-Speed New Energy (01250.HK) reported a total operating power generation of approximately 3.6744 million MWh, an increase of approximately 6.9% year-on-year [3] - Fosun International (00656.HK) reached a settlement with Cainiao regarding a share buyback involving 350 million USD [3] Buyback Activities - Tencent Holdings (00700.HK) repurchased approximately 55 million HKD worth of shares, buying back 919,000 shares at prices ranging from 594.5 to 605 HKD [3] - China Hongqiao (01378.HK) repurchased approximately 22.7 million HKD worth of shares, buying back 8.9235 million shares at a price of 25.44 HKD [3] - HSBC Holdings (00005.HK) repurchased approximately 15.3 million HKD worth of shares, buying back 1.5276 million shares at prices ranging from 99.8 to 100.7 HKD [3] - Hang Seng Bank (00011.HK) repurchased approximately 2.3517 million HKD worth of shares, buying back 210,000 shares at prices ranging from 111.5 to 112.5 HKD [3] - MGM China (02282.HK) repurchased approximately 1.60602 million HKD worth of shares, buying back 1 million shares at prices ranging from 15.92 to 16.27 HKD [3] - Sinopec Engineering (02386.HK) canceled 136,500 shares that had been repurchased [3]

Macroeconomic Dynamics - In July, the bond market issued a total of 77,536.2 billion yuan in various bonds, including 12,226.5 billion yuan in government bonds and 13,496.8 billion yuan in corporate credit bonds [1] - As of the end of July, the bond market's custody balance reached 190.4 trillion yuan, with 168.4 trillion yuan in the interbank market and 22.0 trillion yuan in the exchange market [1] State-Owned Enterprises - From January to July, the total operating revenue of state-owned enterprises remained flat year-on-year at 473,110.9 billion yuan, while total profit decreased by 3.3% to 24,786.4 billion yuan [2] - The tax payable by state-owned enterprises for the same period was 34,694.6 billion yuan, down 0.4% year-on-year [2] - The asset-liability ratio of state-owned enterprises increased by 0.3 percentage points year-on-year to 65.1% as of the end of July [2] Foreign Exchange Market - In July, China's foreign exchange market had a total transaction volume of 28.28 trillion yuan (approximately 3.96 trillion USD), with the interbank market accounting for 24.22 trillion yuan [3] - From January to July, the cumulative transaction volume in the foreign exchange market reached 179.15 trillion yuan (approximately 24.96 trillion USD) [3] Stock Market - As of July 31, the total market capitalization of listed companies in the domestic stock market approached 95 trillion yuan, marking the highest point in nearly three years [4] - There were 5,427 listed companies, with 137 companies having a market capitalization of over 1,000 billion yuan [4] - In July, eight new companies were listed, raising a total of 24.164 billion yuan, while ten companies were delisted [4] Financial Institutions - Agricultural Bank reported a net profit of 139.943 billion yuan for the first half of the year, a year-on-year increase of 2.5% [5] - Postal Savings Bank achieved a net profit of 49.228 billion yuan in the first half of the year, up 0.85% year-on-year [6] Company Dynamics - China National Petroleum Corporation appointed Zhou Xinhai as the new General Manager and Deputy Secretary of the Party Leadership Group [9] - Kweichow Moutai completed a share buyback of 3.9276 million shares, accounting for 0.3127% of its total share capital, with a total buyback amount of 6 billion yuan [10] - China Shipbuilding Industry Corporation's stock will be delisted on September 5, 2025, with shares converted at a ratio of 1:0.1339 to China Shipbuilding's A-shares [14] - Anta Sports and Bosideng both denied rumors regarding potential acquisitions of Canada Goose Holdings Inc. [15]

Core Viewpoint - The Hong Kong stock market experienced a slight rebound on August 29, with innovative drug stocks leading the way, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by 4.41% and recovered from previous losses [1][5]. Market Performance - The trading volume for the day reached 658 million yuan, an increase of 65% compared to the previous day [1]. - Major stocks in the innovative drug sector saw significant rebounds, with companies like Innovent Biologics and CSPC Pharmaceutical rising over 6%, and others like 3SBio and China Biologic Products increasing by more than 5% [2][3]. Stock Highlights - Notable stock performances included: - Green Leaf Pharmaceutical (7.78% increase) - WuXi Biologics (6.96% increase) - Innovent Biologics (6.84% increase) - CSPC Pharmaceutical (6.67% increase) - BeiGene (nearly 4% increase) [4]. Federal Reserve Policy Impact - Following dovish signals from Federal Reserve Chairman Jerome Powell, market expectations for a 25 basis point rate cut in September have risen to over 80% [5]. - The innovative drug sector, being capital-intensive, is expected to benefit from the anticipated easing of monetary policy, which could lead to increased liquidity and growth opportunities [5]. Historical Context - Historical data indicates that during previous Federal Reserve rate cuts (2001-2003, 2008-2009), the Nasdaq Biotechnology Index outperformed the Nasdaq Composite by approximately 40 and 20 percentage points, respectively [5]. - The low-interest-rate environment from 2020 to 2021 led to record high financing in the global innovative drug primary market [5]. Company Performance - BeiGene reported a revenue of 2.433 billion yuan for the first half of the year, a year-on-year increase of 44.73%, with a net profit of 95.59 million USD, exceeding market expectations [6]. - Innovent Biologics also showed strong performance with a revenue of 5.95 billion yuan, a 50.6% year-on-year increase, and a net profit of 1.21 billion yuan [6]. Future Outlook - The innovative drug sector is expected to continue benefiting from domestic policy support, international expansion, and enhanced global competitiveness, which may drive valuation re-rating [6]. - Key catalysts for the second half of the year include medical insurance negotiations, academic conferences, and the implementation of innovative drug directories [6]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a year-to-date increase of 101.58%, significantly outperforming other indices [9][10]. - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on innovative drug companies and has a high concentration of leading stocks [7].

Core Insights - The National Medical Products Administration of China has conditionally approved Zongaitini tablets for the treatment of adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one systemic therapy [1][2] Group 1: Market Context - Lung cancer is the leading cause of cancer-related deaths globally, with an estimated incidence exceeding 3 million cases by 2040. Non-small cell lung cancer is the most common pathological type, and patients typically present at an advanced stage, with a 5-year survival rate of less than 30% [1] - There is a significant unmet medical need for advanced NSCLC patients, particularly those with HER2 mutations, which lead to uncontrolled cell proliferation and tumor growth [1] Group 2: Product Overview - Zongaitini is the first and only oral HER2 tyrosine kinase inhibitor approved globally, previously receiving "breakthrough therapy designation" and "priority review" status in China. It is co-promoted by Boehringer Ingelheim and China National Pharmaceutical Group [2] - The conditional approval is based on positive results from the Beamion-LUNG 1 study, which demonstrated an objective response rate (ORR) of 71% in treated patients, with 7% achieving complete response. The disease control rate (DCR) was 96%, with a median duration of response (DoR) of 14.1 months and a median progression-free survival (PFS) of 12.4 months [2] - The safety profile of Zongaitini is manageable, with a treatment interruption rate of only 2.9% reported in the study [2] Group 3: Expert Commentary - Professor Wu Yilong, Chairman of the Chinese Society of Thoracic Oncology, emphasized that the approval of Zongaitini addresses a critical challenge in NSCLC treatment, providing a new benchmark for HER2-mutated advanced NSCLC patients. This innovative drug offers an efficient, targeted, and oral treatment option for a patient group with poor prognosis and limited treatment choices [3] - Zongaitini's selective design effectively avoids severe skin or gastrointestinal adverse reactions associated with traditional treatments that inhibit EGFR, significantly improving patient tolerance and quality of life [3]

8月29日，港股收盘，恒生指数涨0.32%，恒生科技指数涨0.54%。医药股强劲反弹，荣昌生物涨超 11%，药明康德、信达生物、药明生物涨6%，中国生物制药涨超5%。 ...

Core Viewpoint - China National Medical Products Administration has approved the listing of Zongaitini tablets (brand name: Shenghetu®) for the treatment of adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have received at least one prior systemic therapy [1] Group 1: Product Approval - Zongaitini tablets are the first and currently the only approved oral HER2 tyrosine kinase inhibitor globally [1] - The conditional approval in China is based on positive results from the Beamion-LUNG1 study, which evaluated the efficacy and safety of Zongaitini in patients with advanced NSCLC harboring HER2 (ERBB2) mutations [1] Group 2: Clinical Data - In the treated cohort of previously treated patients (N=75), the objective response rate (ORR) reached 71% (95% CI: 60-80), with 7% achieving complete response [1] - The disease control rate (DCR) was as high as 96%, with a median duration of response (DoR) of 14.1 months and a median progression-free survival (PFS) of 12.4 months [1] - The safety profile of Zongaitini is manageable, with a treatment interruption rate of only 2.9% during the study [1] Group 3: Future Research - Additional research data for TQC3721 (PDE3/4 inhibitor), TQC2731 (TSLP monoclonal antibody), and TQC3403 (Umeclidinium/Vilanterol inhalation powder) will be presented at the ERS 2025 conference [2]

Core Viewpoint - The conditional approval of Zongaitin tablets by the National Medical Products Administration marks a significant advancement in the treatment of HER2-mutated, unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients who have previously received at least one systemic therapy [1][2]. Group 1: Drug Approval and Market Impact - Zongaitin tablets are the first and only oral HER2 tyrosine kinase inhibitor approved globally, previously recognized with "breakthrough therapy designation" and "priority review" in China [2]. - The approval is based on positive results from the Beamion-LUNG1 study, which demonstrated an objective response rate (ORR) of 71% in treated patients, with a complete response rate of 7% and a disease control rate (DCR) of 96% [2]. - The median duration of response (DoR) was 14.1 months, and the median progression-free survival (PFS) was 12.4 months, indicating promising efficacy [2]. Group 2: Clinical Significance and Patient Impact - The approval of Zongaitin addresses a critical challenge in NSCLC treatment, providing a targeted oral medication for HER2 mutations, which previously lacked effective options [3]. - This innovative drug offers a high-efficiency, targeted treatment alternative for a patient group with poor prognosis and limited treatment choices [3]. - Zongaitin's selective design helps avoid severe skin or gastrointestinal adverse reactions associated with traditional treatments, thereby improving patient tolerance and quality of life [3].

Group 1 - China National Medical Products Administration has approved the listing of Zongaitini tablets (brand name: Shenghetu) for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy [1] - Shenghetu is the world's first and currently the only approved oral HER2 tyrosine kinase inhibitor, receiving conditional approval in China based on positive results from the Beamion-LUNG1 study, which evaluated the efficacy and safety of Zongaitini in patients with advanced NSCLC with HER2 (ERBB2) mutations [1] - In the treated cohort of previously treated patients (N=75), the objective response rate (ORR) reached 71% (95% CI: 60-80), with 7% achieving complete response, and the disease control rate (DCR) was as high as 96% [1] Group 2 - Lung cancer remains the leading cancer type globally and in China, with significant unmet clinical needs [2] - The approval of Shenghetu in China will provide a more effective and compliant treatment option for many HER2-mutated non-small cell lung cancer patients, further enriching the company's product line in the oncology field [2] - The company aims to bring therapeutic benefits to more patients with the motto "Health technology, warming more lives" [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 宗艾替尼片獲批上市 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團與 勃林格殷格翰在中國大陸聯合推廣的宗艾替尼片（商品名：聖赫途® ）已獲得中國國家藥品監督管理局 的上市批准，用於治療存在HER2（ERBB2）激活突變且既往接受過至少一種系統治療的不可切除的局 部晚期或轉移性非小細胞肺癌（NSCLC）成人患者。 1 肺癌無論在全球還是中國，均為第一大癌種，臨床仍存在巨大的未滿足治療需求。聖赫途®在中國獲 批，將為國內眾多HER2突變非小細胞肺癌患者帶來更高效、依從性更佳的治療選擇，也將進一步豐 富本集團在腫瘤領域的產品線，爭取為更多患者帶來治療獲益，用『健康科技，溫暖更多生命』。 [1] Heymach, J. et al. Zongert ...

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 4.0% as of 14:50, and notable increases in stocks such as Luye Pharma (over 8%) and CSPC Pharmaceutical Group (over 7%) [1] - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Analysts suggest that with the onset of a global interest rate cut cycle, there is significant potential for Chinese innovative drugs to capitalize on international opportunities, potentially leading to breakthroughs in the global innovative drug industry [1] Group 2 - The Hang Seng Innovative Drug Index has recently undergone adjustments to exclude contract research organizations (CROs), resulting in a "pure" index that more accurately reflects the performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index and has been attracting significant investment, aiding investors in strategically positioning themselves within the innovative drug sector [2]